1. Home
  2. NVAX vs AMPH Comparison

NVAX vs AMPH Comparison

Compare NVAX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • AMPH
  • Stock Information
  • Founded
  • NVAX 1987
  • AMPH 1996
  • Country
  • NVAX United States
  • AMPH United States
  • Employees
  • NVAX N/A
  • AMPH N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • AMPH Health Care
  • Exchange
  • NVAX Nasdaq
  • AMPH Nasdaq
  • Market Cap
  • NVAX 2.0B
  • AMPH 2.5B
  • IPO Year
  • NVAX 1995
  • AMPH 2014
  • Fundamental
  • Price
  • NVAX $9.76
  • AMPH $51.45
  • Analyst Decision
  • NVAX Buy
  • AMPH Buy
  • Analyst Count
  • NVAX 6
  • AMPH 4
  • Target Price
  • NVAX $17.83
  • AMPH $63.00
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • AMPH 268.7K
  • Earning Date
  • NVAX 11-07-2024
  • AMPH 11-06-2024
  • Dividend Yield
  • NVAX N/A
  • AMPH N/A
  • EPS Growth
  • NVAX N/A
  • AMPH 62.07
  • EPS
  • NVAX N/A
  • AMPH 3.15
  • Revenue
  • NVAX $987,667,000.00
  • AMPH $712,891,000.00
  • Revenue This Year
  • NVAX N/A
  • AMPH $18.04
  • Revenue Next Year
  • NVAX N/A
  • AMPH $4.41
  • P/E Ratio
  • NVAX N/A
  • AMPH $16.26
  • Revenue Growth
  • NVAX N/A
  • AMPH 31.80
  • 52 Week Low
  • NVAX $3.53
  • AMPH $36.56
  • 52 Week High
  • NVAX $23.86
  • AMPH $65.92
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 36.20
  • AMPH 59.40
  • Support Level
  • NVAX $9.52
  • AMPH $49.38
  • Resistance Level
  • NVAX $10.63
  • AMPH $51.84
  • Average True Range (ATR)
  • NVAX 0.57
  • AMPH 1.25
  • MACD
  • NVAX -0.12
  • AMPH 0.10
  • Stochastic Oscillator
  • NVAX 9.97
  • AMPH 78.90

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: